GlassScriptPhysician profile
Priya Rangasamy
NPI 1598963746
$3,615.69
in general payments reported to CMS, 2019-2025
28 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $133 · 2021: $452 · 2022: $340 · 2023: $587 · 2024: $1,095 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,472 · Education: $21.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,471.65 |
| Education | $21.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $819.75 | 2020-2025 | |
| Pfizer INC. | $473.79 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.53 | 2020-2025 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $313.17 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Celltrion USA INC. | $240.47 | 2024-2025 | Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $164.45 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $155.58 | 2024-2025 | Dupixent |
| Shionogi INC | $141.72 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.94 | 2021-2025 | Entyvio |
| Redhill Biopharma INC. | $101.01 | 2022-2023 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $100.95 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $70.25 | 2021 | |
| Evoke Pharma, INC. | $54.28 | 2020-2021 | |
| Lilly USA, LLC | $52.66 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $47.06 | 2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.07 | 2023-2024 | Cyltezo |
| Ardelyx, INC. | $40.42 | 2024-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $39.98 | 2023 | Rebyota |
| Alfasigma USA, INC. | $34.44 | 2020-2022 | |
| Braintree Laboratories, INC. | $30.92 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $25.49 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $22.99 | 2025 | Iqirvo |
| Ethicon US, LLC | $19.01 | 2021 | |
| Qol Medical, LLC | $17.08 | 2022 | |
| Enterra Medical, INC. | $15.73 | 2024 | |
| Aimmune Therapeutics, INC. | $15.12 | 2025 | Vowst |
| Allergan, INC. | $11.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,851.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Rangasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.